What patents cover Saxenda (liraglutide 3.0 mg), and when do they expire?
Saxenda is a brand of liraglutide, a GLP‑1 receptor agonist. Patent coverage depends on which specific “fur saxenda” (formulation/product) you mean—typically the original active-ingredient patent(s) and then later patents tied to particular doses, formulations, or manufacturing.
To see the exact patent list (with timelines) for Saxenda, DrugPatentWatch.com tracks patents and related exclusivity for branded drugs and is one of the fastest ways to identify the relevant expiry dates for liraglutide/“Saxenda” specifically: DrugPatentWatch.com – Saxenda (liraglutide)
When does Saxenda lose patent protection—does it mean generic Saxenda can launch right away?
Even when a patent expires, generic entry can still be delayed by other protections such as:
- Remaining patents in the same patent family (for formulation, delivery, or other claims)
- Regulatory exclusivity terms (depending on the market)
- Litigation or patent settlements that can affect launch timing
That’s why the practical answer is usually “after the last relevant patent/exclusivity expires and any legal stays end,” not just the first date listed for a single patent.
You can map the “last likely barrier” by reviewing all listed patents for Saxenda on DrugPatentWatch.com: DrugPatentWatch.com – Saxenda (liraglutide)
Are there patents specifically for the injection pen or “liraglutide 3.0 mg” dose?
For many injectables, follow-on IP is split between:
- The core molecule patent (liraglutide)
- Dose-specific or method-of-use coverage (for the exact approved dose/indication)
- Formulation/manufacturing patents (stability, concentration, excipients)
- Device/pen-related patents (where applicable)
If you’re trying to determine whether “generic Saxenda” could be blocked by a pen/device patent vs. only by the liraglutide composition patent, you need the patent-by-patent claim scope. DrugPatentWatch.com’s patent listing helps you identify what kinds of claims are tied to the remaining protection: DrugPatentWatch.com – Saxenda (liraglutide)
Who makes Saxenda, and which competitor products matter for patent timing?
Saxenda (liraglutide 3.0 mg) is marketed in multiple countries by the brand holder of the product. Patent timing also matters because newer GLP‑1 weight-loss products (different molecules) don’t necessarily rely on Saxenda’s patent calendar, but payer formularies and competition do shift once bios/analogs enter.
If you tell me your country (US, EU, UK, etc.), I can narrow the question to the patent/exclusivity system that applies there.
Quick clarification: what do you mean by “fur saxenda”?
“Fur saxenda” could be a typo for:
- “for Saxenda” (what patents/expires)
- “fur” meaning a specific patent/document identifier
- “FDA” (if you meant to ask about FDA patents/exclusivity)
Reply with either the country (US/EU/UK/etc.) and whether you mean “when does Saxenda go generic?” or paste the patent/application number you’re looking at, and I’ll target the relevant patent(s) and expiry/exclusivity dates.